Carregant...
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma
The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors). This review will focus on ixazomib, an orally bioavailable second-generatio...
Guardat en:
| Publicat a: | Ther Adv Hematol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5495505/ https://ncbi.nlm.nih.gov/pubmed/28694935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717710171 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|